Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldafermin Pharmacokinetics in Impaired Hepatic Function
NCT04823702Phase 1Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of aldafermin in Nonalcoholic steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by NGM Biopharmaceuticals. Primary endpoint: Pharmacokinetics of Aldafermin at 4 days. Started Apr 2021; status: completed.
02
Drugs
aldafermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT04823702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823702.